Genmab — Oktober 2023
-
SITC Abstract 813- Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro https://jitc.bmj.com/content/11/Suppl_1/912
-
SITC23 Abstract 1181- GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody
-CD40x4-1BB), exhibits in vivo antitumor activity and peripheral immune modulation https://jitc.bmj.com/content/11/Suppl_1/1302 -
SITC23
681- innovaTV 207 Parts E and F: A phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress) https://jitc.bmj.com/content/11/Suppl_1/772 -
Tepezza sales not yet included in the Amgen sales, but discussed in the call Q3 '23 -In the third quarter, sales of Tepezza reached $453 million, the company said on Tuesday. While Amgen was quick to point out that it was a 2% increase from the previous quarter, it also was an 8% decline year over year. Amgen has a plan to get Tepezza’s groove back, using a playbook that the company employed with vasculitis drug Tavneos after its 2020 acquisition of Chemocentryx.
-
-
https://www.irishtimes.com/business/2023/10/25/irish-jobs-to-go-as-amgen-cuts-350-horizon-employees-after-takeover/ Detvar så kun ca 20% de fyrede. Men lidt omstilling vil koste på omsætningen kortvarigt må man vel forvente. Spændende hvad den store organisation kan gøre ved Tapezza.
-
Jeg fandt lige følgende fra Handelsbanken dateret oktober 2022 angående Hexabody CD38 »For indeværende indikerer de prækliniske data for Hexabody-CD38, at antistoffet er ti gange mere potent end Darzalex, om end sikkerhedsprofilen endnu ikke er bekræftet. Endelige forsøgsdata vil blive offentliggjort i de kommende 12-18 måneder,« skriver Handelsbanken i sit morgenbrev. Har vi ikke hørt yderligere det seneste år.?
-
Der er denne artikel fra juni, men resultater fra klinikken holder de tæt til kroppen: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00228-1/fulltext
-
Vi har Plesners udtalelse fra april sidste år: “ Efter vi påbegyndte studiet for et år siden har vi nu formået at nå den maksimale påtænkte dosis uden nogen alvorlige bivirkninger, hvilket er det primære formål for studiets fase I, og det er meget positivt,” siger han.
-
Mere effektiv version af daratumumab tyder lovende i tidlige forsøg
Sidste år begyndte et nyt in human-forsøg med en ny modificeret udgave af blockbuster-præparatet Darzalex (daratumumab) på Vejle Sygehus. De foreløbige resultater viser, at midlet er veltolereret ved dosisopskalering til behandling af recidiv myelomatose, og det giver grund til optimisme.
(haematologisktidsskrift.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind